Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria.
OBJECTIVE
To examine whether the progression of early diabetic renal disease to end-stage renal failure may be slowed by the use of angiotensin converting enzyme inhibitors for reasons other than their antihypertensive properties, so that they have value in the treatment of normotensive diabetics with microalbuminuria.


METHODS
Medline was searched for English language reviews and randomised controlled trials. Personal reference lists, and reference lists of retrieved studies were also used.


METHODS
Randomised controlled trials with separate identifiable results for initially normotensive diabetic patients, who received angiotensin converting enzyme inhibitors for at least one year and were compared with controls.


METHODS
Meta-analyses were performed on the results of 12 randomised controlled trials with a variety of patient inclusion and exclusion criteria. One further study met all conditions for inclusion but did not provide data in useable form for meta-analyses.


RESULTS
Albumin excretion rate fell for patients on angiotensin converting enzyme inhibition in 12 of the 13 studies but did so for only two of the 13 groups on placebo. Treatment provided a significant reduction in albumin excretion rate in both insulin dependent diabetes mellitus and non insulin dependent diabetes mellitus. Treatment with either captopril, enalapril or lisinopril reduced albumin excretion rate in comparison with control patients. A significantly greater lowering of blood pressure was experienced by initially normotensive patients in the angiotensin converting enzyme inhibitor than in the placebo group. Average glycosylated haemoglobin fell a little in the treated patients and rose in the controls, the difference being just significant. The difference in changes in glomerular filtration rate did not reach statistical significance.


CONCLUSIONS
Inhibition of angiotensin converting enzyme can arrest or reduce the albumin excretion rate in microalbuminuric normotensive diabetics, as well as reduce or prevent an increase in blood pressure. But, given the drop in blood pressure in patients on angiotensin converting enzyme inhibitors, it is not certain that the reduction of albumin excretion rate is due to a separate renal effect. A direct link with postponement of end-stage renal failure has not been demonstrated. There appear to be no substantial side effects.
2 Ardencaple Drive, Helensburgh, Dunbartonshire, UK, G84 8PS.
H G
HG
Lovell
D000419:Albuminuria / Q000150:complications* / Q000188:drug therapy; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic
D000806:Angiotensin-Converting Enzyme Inhibitors